|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
UNDER CONSTRUCTION | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Saturday, September 16, 2006
NEW MS DRUG IN PIPELINE: STANFORD UNIVERSITY APPLIES FOR PATENT...FULL ARTICLE
"Method of treating rheumatoid arthritis and MS ...: "Applicant The Board of Trustees of the Leland Stanford Junior University...Inventor(s) Godfrey, Wayne Engleman, Edgar G.....Abstract The invention provides ligands and fragments thereof to a receptor on the surface of activated CD4+T-cells. An exemplary ligand is designated ACT-4-L-h-1. Preferred fragments include purified extracellular domains of ligands. The invention also provides humanized and human antibodies to the ligand. The invention further provides methods of using the ligand and the antibodies in treatment of diseases and conditions of the immune system. The invention also provides methods of monitoring activated CD4+T-cells using the ligands or fragments thereof. If you would like to purchase a copy of this patent, please call MicroPatent at 800-648-6787." |